All News
Survival and Mortality in RA: time to move away from “one-size fits all”?
Patients with RA are known to have a higher mortality risk than the general population.
Read Article
VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a
Max Konig MaxKonigMD ( View Tweet)
Yr in review #ACR22 @RheumNow
🌟GLORIA 2 yr data:
👉Pred 5mg OD vs PBO >65y/o RA
✅⬇️ disease activity (DAS28 -0.38)
✅⬇️ joint damage (sharp/van der heijde -1.7)
❌ 24% ⬆️ a/e
“Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”
Patricia Harkins DrTrishHarkins ( View Tweet)
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Robert B Chao, MD doctorRBC ( View Tweet)
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Julian Segan JulianSegan ( View Tweet)
Year in Review
#ACR22
Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies
@RheumNow https://t.co/EPtOrjJqLd
Eric Dein ericdeinmd ( View Tweet)
Preview of what is sure to be discussed more in detail later..
MIRROR trial of MTX co-administration with pegloticase in treatment of gout.
MTX co-administration improved control of gout, reduced infusion reactions
@RheumNow #ACR22 https://t.co/r0MEq1rkgO
Robert B Chao, MD doctorRBC ( View Tweet)
ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
#ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh
TheDaoIndex KDAO2011 ( View Tweet)
Year in review #ACR22
IVIG received FDA approval for dermatomyositis in 2022!
@RheumNow
Bella Mehta bella_mehta ( View Tweet)
Year in Review #ACR22
IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo
First approved Rx for inflammatory myositis
@RheumNow https://t.co/T6qVTQQdTp
Eric Dein ericdeinmd ( View Tweet)
Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDiBdJZn) a few eps back
I disagree w/Dr. Langford re:role in therapy. I use IVIG first line for most all pts w/myositis, grateful for the FDA approval!
#ACR22 @RheumNow https://t.co/BfHZm4Kl49
Mike Putman EBRheum ( View Tweet)
Folle et al propose a neural network to differentiate RA+ & RA- vs PsA w/ AUROC 75% & 67% for RA+ vs RA- in 5 distinct hands MRI sequences. Question: what was the performance of the rheumatologist or radiologist?
https://t.co/93aZKPlKsO
Abstr#0242 #ACR22 @Rheumnow https://t.co/uk2c3gbAOT
Aurelie Najm AurelieRheumo ( View Tweet)
Year in Review #ACR22
CAR T cells: deep depletion of CD19 leading to immune reset
5 patients with active SLE
Normalizations of complements, dsDNA
Drug free remission
3 will mild immune reconstitution symptoms, 1 received tocilizumab
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Nice chart w/JAKs/TYKs by drug and by cytokine pathways
In reality there is a fair bit of crossover and "selectives" aren't nearly as selective as this implies
Helpful to add deucravacitinib to the list! Looking forward to upcoming plenary
#RheumNow #ACR22 #YearInReview https://t.co/MERzpvrFB9
Mike Putman EBRheum ( View Tweet)
Nice summary slide of JAK inhibitors and the history of JAKi in rheumatology,
#ACR22 #ACRambassador https://t.co/Ij2D7YikjT
Vaneet K Sandhu, MD, RhMSUS (she/her) vksandhumd ( View Tweet)
Day 1 #ACR22. Tips to avoid burnout: stretch your legs, a change in scenery for virtual attendees, replenish your sweets and savoury and importantly keep your furry friend happy 🐈⬛ #PetsAtACR @RheumNow #RheumPix https://t.co/opGVSjxLjE
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
Eric Dein ericdeinmd ( View Tweet)
Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1
TheDaoIndex KDAO2011 ( View Tweet)
GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5!
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan JulianSegan ( View Tweet)